Job Title
Professor of Oncology
Department
WMS - Cancer Research
Phone
02476967497
- Conefrey, C., Donovan, J. L., Stein, R. C., Paramasivan, S., Marshall, Andrea, Bartlett, J., Cameron, D. A., Campbell, Amy, Dunn, Janet A., Earl, H., Hall, P., Harmer, V., Hughes-Davies, L., Macpherson, I., Makris, A., Morgan, A., Pinder, S. E., Poole, Christopher J., Rea, D., Rooshenas, L., 2020. Strategies to improve recruitment to a de-escalation trial : a mixed-methods study of the OPTIMA prelim trial in early breast cancer. Clinical Oncology
- Fernando, Indrajit N., Bowden, Sarah J., Herring, Kathryn, Brookes, Cassandra L., Ahmed, Ikhlaaq, Marshall, Andrea, Grieve, Robert J., Churn, Mark, Spooner, David, Latief, Talaat N., Agrawal, Rajiv K., Brunt, Adrian M., Stevens, Andrea, Goodman, Andrew, Canney, Peter, Bishop, Jill, Ritchie, Diana, Dunn, Janet A., Poole, Christopher J., Rea, Daniel W., 2020. Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB) : a randomised, phase III, trial. Radiotherapy and Oncology, 142, pp. 52-61
- Jepson, Marcus, Elliott, Daisy, Conefrey, Carmel, Wade, Julia, Rooshenas, Leila, Wilson, Caroline, Beard, David, Blazeby, Jane M., Birtle, Alison, Halliday, Alison, Stein, Rob, Donovan, Jenny L., Beard, David, Carr, Andrew, Cook, Jonathan, Cooper, Cushla, Dean, Benjamin, Donovan, Jenny L., Gray, Alastair, Gwilym, Stephen et al (Select to open full list), 2018. An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Journal of Clinical Epidemiology, 99, pp. 75-83
- Guo, Qi, Burgess, Stephen, Turman, Constance, Bolla, Manjeet K., Wang, Qin, Lush, Michael, Abraham, Jean, Aittomäki, Kristiina, Andrulis, Irene L, Apicella, Carmel, Arndt, Volker, Barrdahl, Myrto, Benitez, Javier, Berg, Christine D., Blomqvist, Carl, Bojesen, Stig E, Bonanni, Bernardo, Brand, Judith S, Brenner, Hermann, Broeks, Annegien et al (Select to open full list), 2017. Body mass index and breast cancer survival : a Mendelian randomization analysis. International Journal of Epidemiology, 46 (6), pp. 1814-1822
- Dorling, L, Kar, Siddhartha, Michailidou, Kyriaki, Hiller, Louise, Vallier, Anne-Laure, Ingle, Susan, Hardy, Richard, Bowden, Sarah J., Dunn, Janet A., Twelves, Chris, Poole, Christopher J., Caldas, Carlos, Earl, Helena M., Pharoah, Paul D. P., Abraham, Jean E., 2016. The relationship between common genetic markers of breast cancer risk and chemotherapy-induced toxicity : a case-control study. PLoS One, 11 (7)
- Bartlett, J. M. S., McConkey, Christopher C., Munro, A. F., Desmedt, C., Dunn, Janet A., Larsimont, D., O'Malley, F. P., Cameron, D. A., Earl, H., Poole, Christopher J., Shepherd, L. E., Cardoso, F., Jensen, M., Caldas, C., Twelves, C. J., Rea, D. W., Ejlertsen, B., Di Leo, A., Pritchard, K. I., 2015. Predicting anthracycline benefit : TOP2A and CEP17-not only but also. European Journal of Cancer Care, 33 (15), pp. 1680-1687
- Bartlett, J., Canney, P., Campbell, A. M., Cameron, D., Donovan, Jenny, Dunn, Janet A., Earl, Helena M., Francis, A., Hall, P., Harmer, V., Higgins, Helen B., Hillier, L., Hulme, C., Hughes-Davies, Luke, Makris, A., Morgan, A., McCabe, Chris, Pinder, S., Poole, Christopher J., Rea, D. et al (Select to open full list), 2013. Selecting breast cancer patients for chemotherapy : the opening of the UK OPTIMA trial. Clinical Oncology, 25 (2), pp. 109-116
- Ali, Alaa M., Provenzano, E., Barlett, J. M., Abraham, J., Driver, Kristy, Twelves, Chris, Munro, Alison F., Poole, Christopher, Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul, 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic subtypes in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
- Ali, Alaa M., Provenzano, Elena, Bartlett, John M. S., Abraham, Jean, Driver, Kristy, Munro, Alison F., Twelves, Chris, Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Earl, Helena M., Caldas, Carlos, Pharoah, Paul D., 2013. Prognosis of early breast cancer by immunohistochemistry defined intrinsic sub-types in patients treated with adjuvant chemotherapy in the NEAT/BR9601 trial. International Journal of Cancer, 133 (6), pp. 1470-1478
- Earl, Helena M., Hiller, Louise, Dunn, Janet A., Vallier, A. -L., Bowden, S. J., Jordan, S. D., Blows, F., Munro, A., Bathers, S., Grieve, R., Spooner, David A., Agrawal, R., Fernando, I., Brunt, A. M., O'Reilly, S. M., Crawford, S. Michael, Rea, D. W., Simmonds, P., Mansi, J. L., Stanley, A. et al (Select to open full list), 2012. Adjuvant epirubicin followed by cyclophosphamide, methotrexate and fluorouracil (CMF) vs CMF in early breast cancer : results with over 7 years median follow-up from the randomised phase III NEAT/BR9601 trials. British Journal of Cancer, Vol.107 (No.8), pp. 1257-1267
- Campbell, H. E., Epstein, D., Bloomfield, D., Griffin, S., Manca, A., Yarnold, J., Bliss, J., Johnson, L., Earl, Helena M., Poole, Christopher J., Hiller, Louise, Dunn, Janet A., Hopwood, P., Barrett-Lee, P., Ellis, P., Cameron, D., Harris, A. L., Gray, A. M., Sculpher, Mark J., 2011. The cost-effectiveness of adjuvant chemotherapy for early breast cancer : a comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. European Journal of Cancer, Vol.47 (No.17), pp. 2517-2530
- Leo, Angelo Di, Desmedt, Christine, Bartlett, John M. S., Piette, Fanny, Ejlertsen, Bent, Pritchard, Kathleen I., Larsimont, Denis, Poole, Christopher J., Isola, Jorma, Earl, Helena M., Mouridsen, H. T., O'Malley, Frances P., Cardoso, Fatima, Tanner, Minna, Munro, A., Twelves, Chris, Sotiriou, Christos, Shepherd, Lois, Cameron, D., Piccart, Martine J. et al (Select to open full list), 2011. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer : a meta-analysis of individual patient data. Lancet Oncology, Vol.12 (No.12), pp. 1134-1142
- Rustin, G., Reed, N., Jayson, G. C., Ledermann, J. A., Adams, M., Perren, T., Poole, Christopher, Lind, M., Persic, M., Essapen, S., Gore, M., Calvert, H., Stredder, C., Wagner, A., Giurescu, M., Kaye, S., 2011. A phase II trial evaluating two schedules of sagopilone (ZK-EPO), a novel epothilone, in patients with platinum-resistant ovarian cancer. Annals of Oncology, Vol.22 (No.11), pp. 2411-2416
- Forster, Martin D., Dedes, Konstantin J., Sandhu, Shahneen, Frentzas, Sophia, Kristeleit, Rebecca, Ashworth, Alan, Poole, Christopher J., Weigelt, Britta, Kaye, Stan B., Molife, L. Rhoda, 2011. Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nature Reviews. Clinical Oncology, 8 (5), pp. 302-306
- Bartlett, John M. S., Munro, Alison F., Dunn, Janet A., McConkey, Christopher C., Jordan, S., Twelves, Chris, Cameron, D., Thomas, Jeremy St. J., Campbell, Fiona M., Rea, Daniel W., Provenzano, Elena, Caldas, Carlos, Pharaoh, Paul, Hiller, Louise, Earl, Helena M., Poole, Christopher, 2010. Predictive markers of anthracycline benefit : a prospectively planned analysis of the UK national epirubicin adjuvant trial (NEAT/BR9601). Lancet Oncology, Vol.11 (No.3), pp. 266-274
- Ellis, Paul, Barrett-Lee, Peter, Johnson, Lindsay, Cameron, David, Wardley, Andrew, O'Reilly, Susan, Verrill, Mark, Smith, Ian, Yarnold, John, Coleman, Robert, Earl, Helena M., Canney, Peter, Twelves, Chris, Poole, Christopher J., Bloomfield, David, Hopwood, Penelope, Johnston, Stephen, Dowsett, Mitchell, Bartlett, John M. S., Ellis, Ian et al (Select to open full list), 2009. Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT) : an open-label, phase III, randomised controlled trial. Lancet, Vol.373 (No.9676), pp. 1681-1692
- Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, S., Harvey, P., Stanley, A., Grieve, R. J., Agrawal, R. K., Fernando, I. N., Brunt, A. M., McAdam, K., O'Reilly, S., Rea, D. W., Spooner, David A., Poole, Christopher, 2008. NEAT : national epirubicin adjuvant trial - toxicity, delivered dose intensity and quality of life. British Journal of Cancer, Vol.99 (No.8), pp. 1226-1231
- Wardley, A. M., Hiller, Louise, Howard, H. C., Dunn, Janet A., Bowman, A., Coleman, R. E., Fernando, I. N., Ritchie, D. M., Earl, Helena M., Poole, Christopher J., 2008. tAnGo : a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer : a prospective pulmonary, cardiac and hepatic function evaluation. British Journal of Cancer, Vol.99 (No.4), pp. 597-603
- Kaye, Stan B., Poole, Christopher, Bidzinksi, M., Gianni, L., Gorbunova, V., Novikova, E., Strauss, A., McNally, V. A., Rossi, G., Vergote, Ignace, 2008. A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab (P) versus carboplatin-based therapy alone in patients with relapsed, platinum sensitive ovarian cancer. Journal of Clinical Oncology, Vol.26 (No.15S)
- Poole, Christopher J., Earl, Helena M., Hiller, Louise, Dunn, Janet A., Bathers, Sarah, Grieve, Robert J., Spooner, David A., Agrawal, Rajiv K., Brunt, A. Murray, O'Reilly, Susan M., Crawford, S. Michael, Rea, Daniel W., Simmonds, Peter, Mansi, Janine L., Stanley, Andrew, Harvey, Peter, McAdam, Karen, Foster, Liz, Leonard, Robert C. F., Twelves, Chris, 2006. Epirubicin and cyclophosphamide, methotrexate,and fluorouracil as adjuvant therapy for early breast cancer. New England Journal of Medicine, Vol.355 (No.18), pp. 1851-1862
- Poole, Christopher J., Lisyanskaya, A., Rodenhuis, S., Kristensen, G., Lauraine, E. Pujade, Cantarini, M., Emeribe, U., Stuart, M., Coquard, I. Ray, 2010. A randomized phase II clinical trial of the SRC inhibitor saracatinib (AZD0530) and carboplatin plus paclitaxel (C plus P) versus C plus P in patients (pts) wiht advanced platinum-sensitive epithelial ovarian cancer (eoc). 35th European-Society-for-Medical-Oncology (ESMO) Congress, Milan, Italy, 8-12 Oct 2010, Published in Annals of Oncology, pp. 304-305
- Bartlett, John M. S., Munro, A., O'Malley, Frances P., Earl, Helena M., Poole, Christopher J., Cardoso, Fatima, Twelves, Chris, Pritchard, Kathleen I., Rea, Daniel W., Di Leo, A., 2010. Duplication of chromosome 17 CEP predicts for anthracycline benefit: evidence from an international meta-analysis of 4 adjuvant breast cancer trials for the HER2/TOP2A meta-analysis study group. European Breast Cancer Conference, Barcelona, Spain, March 24, 2010, Published in European Journal of Cancer Supplements, pp. 121-121
- Bartlett, J. M. S., Munro, A., Dunn, Janet A., Hiller, Louise, Jordan, S., Twelves, Chris, Cameron, D. A., Thomas, J., Campbell, F., Rea, D. W., Provenzano, E., Pharoah, P., Caldas, Carlos, Earl, Helena M., Poole, Christopher J., 2009. Chromosome 17 polysomy (Ch17) as a predictor of anthracycline response: emerging evidence from the UK NEA Tadjuvant breast cancer trial. 31st Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 10-14, 2008, Published in Cancer Research, pp. 74S-74S
- Bartlett, J. M. S., Munro, A., Desmedt, Christine, Dunn, Janet A., Larsimont, D., O'Malley, F. P., Cameron, D. A., Earl, Helena M., Poole, Christopher J., Shepherd, Lois, Cardoso, Fatima, Caldas, Carlos, Twelves, Chris, Pritchard, K., Rea, D. W., di Leo, A., 2009. Duplication of chromosome 17 CEP predicts for anthracycline benefit: a meta-analysis of 4 trials. 32nd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, DEC 09-13, 2009, Published in Cancer Research, pp. 716S-716S
- Gray, R. G., Rea, Dean, Handley, K., Marshall, A. (Andrea), Pritchard, M. G., Perry, P., Earl, Helena M., Poole, Christopher J., Salman, A., Lee, M., 2008. aTTom (adjuvant Tamoxifen--To offer more?) : randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer--Preliminary results. 2008 ASCO Annual Meeting, Chicago, Illinois, 30 May-3 Jun 2008, Published in Journal of Clinical Oncology
- Bartlett, J. M. S., Stein, R. C., Bayani, J., Marshall, A. (Andrea)?, Dunn, Janet A., Campbell, A. F., Cunningham, C., Sobol, M., Hall, P., Rooshenas, L., Morgan, A., Poole, Christopher J., Pinder, S. E., Cameron, D. A., Stallard, Nigel, Donovan, J., McCabe, C., Hughes-Davies, L., Makris, A., 2015. Comparison of multiparameter tests in the UK OPTIMA-Prelim trial. Cancer Research, American Association of Cancer Research
- Poole, Christopher J., Marshall, A. (Andrea)?, Higgins, Helen B., Fletcher, J., Williams, S. J., Lo, N., Fernando, I. N., Osborne, R., Crawford, S. M., Rafii, S., Gill, S., Dunn, Janet A., 2012. Neo-escape : Neoadjuvant extended sequential chemotherapy with adjuvant postoperative treatment for epithelial nonmucinous advanced inoperable peritoneal malignancy. Journal of Clinical Oncology, American Society of Clinical Oncology
- Marshall, A. (Andrea), Dunn, Janet A., Fletcher, Julie, Higgins, Helen B., Poole, Christopher, 2011. The importance of planning for a seamless transition in an adaptive phase II randomised trial. Trials, Bio Med Central
Title | Funder | Award start | Award end |
---|---|---|---|
BAYER - Investigator led research proposal: *SELECT-D* Duration of anticoagulation therapy in SELECTeD patients with advanced cancer at risk of recurrence of venous thromboembolism - | Bayer plc | 01 Oct 2012 | 30 Sep 2015 |
NEOESCAPE - Neoadjuvant extended sequential chemotherapy with adjuvant post-operative treatment with epithelial ovarian cancer | Cancer Research UK | 01 Oct 2008 | 30 Sep 2009 |